Renal Dosing for Eliquis (Apixaban)

Dosing Recommendations by Renal Function Category

• The American Heart Association, American College of Cardiology, and Heart Rhythm Society recommend a standard dose of 5 mg twice daily for patients with normal renal function or mild impairment 1, 2
• No dose adjustment is needed for creatinine clearance (CrCl) >30 mL/min, as stated by the American College of Cardiology 2
• For patients with moderate renal impairment (CrCl 30-50 mL/min), the standard dose of 5 mg twice daily is recommended by the American Heart Association and American College of Cardiology 1, 2
• The dose should be reduced to 2.5 mg twice daily if the patient has at least two of the following: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL, according to the American Heart Association and American College of Cardiology 1, 2

Severe Renal Impairment

• European guidelines indicate that apixaban can be used in severe chronic kidney disease (CKD) with dose reduction 3
• Apixaban has the lowest renal clearance (27%) among direct oral anticoagulants, making it potentially preferable in patients with severe renal impairment, as stated in the European Heart Journal 3

End-Stage Renal Disease on Dialysis

• The American College of Cardiology recommends that apixaban 5 mg twice daily can be used in patients with end-stage renal disease (ESRD) on stable hemodialysis, with dose reduction to 2.5 mg twice daily if the patient is ≥80 years of age or body weight is ≤60 kg 2

Important Considerations

Monitoring Renal Function

• The American Heart Association and American College of Cardiology recommend that renal function should be evaluated before initiation of apixaban and reassessed at least annually and when clinically indicated 1, 2
• Creatinine clearance should be calculated using the Cockcroft-Gault method, as recommended by the American Heart Association and American College of Cardiology 1, 2

Drug Interactions

• The American College of Cardiology states that P-glycoprotein inhibitors may increase apixaban plasma concentrations 2
• Concomitant use of dual P-glycoprotein and strong CYP3A4 inducers or inhibitors may require dosing adjustment or avoidance, particularly in patients with CKD, according to the American Heart Association and American College of Cardiology 1, 2

Bleeding Risk

• Patients with severe renal impairment have increased bleeding risk with all anticoagulants, as stated in the European Heart Journal 3

Apixaban Dosing Based on Renal Function

Introduction to Apixaban Dosing

• The European Heart Journal recommends apixaban, which has the lowest renal clearance (27%) among direct oral anticoagulants, making it potentially preferable in patients with renal impairment 4

Dosing Considerations for Renal Impairment

• For patients with moderate renal impairment (ClCr 30-50 mL/min), the last dose of apixaban should be administered 3-4 days before elective surgery, depending on the bleeding risk 5
• The European Heart Journal approves apixaban with a reduced dosing regimen for severe chronic kidney disease (Stage 4) 4
• The recommended dose is 2.5 mg twice daily in patients with severe renal impairment (ClCr 15-29 mL/min) 4

Pharmacokinetics and Pharmacodynamics

• Apixaban may be preferable over other direct oral anticoagulants due to its lower renal clearance 4
• The European Heart Journal notes that apixaban produces supratherapeutic levels at a dose of 5 mg twice daily in patients on chronic hemodialysis 4
• A dose of 2.5 mg twice daily produces exposure to the drug similar to the standard dose in patients with normal renal function, according to pharmacokinetic data 4

Specific Indications and Conditions

• The Journal of the National Comprehensive Cancer Network excludes patients with ClCr <15 mL/min or serum creatinine >2.5 mg/dL from clinical trials 6

Considerations for Patients on Dialysis

• The European Heart Journal notes that warfarin can cause calciphylaxis, a painful and often lethal condition in patients with end-stage renal disease 4

Anticoagulation Therapy in Renal Impairment

Introduction to Anticoagulant Switching

• The American Heart Association recommends switching from dabigatran to apixaban when creatinine clearance falls below 50 mL/min, especially in the range of 30-50 mL/min, where apixaban's pharmacokinetic profile offers significant safety advantages 7, 8

Dosing Considerations

• In patients with moderate renal impairment (CrCl 30-50 mL/min), apixaban is preferred due to its lower renal elimination rate, with a recommended dose of 5 mg twice daily unless the patient meets ≥2 of the 3 dose reduction criteria 8
• Dabigatran requires dose reduction to 110 mg twice daily in patients with moderate renal impairment and additional risk factors, but its use is not recommended in severe renal impairment (CrCl 15-30 mL/min) due to lack of established safety and efficacy 7, 8

Renal Function-Based Decision Making

• For patients with severe renal impairment (CrCl 15-30 mL/min), apixaban is clearly preferred, with a recommended dose of 5 mg twice daily, reducible to 2.5 mg twice daily in certain cases 7, 8
• In end-stage renal disease on dialysis, dabigatran is contraindicated, while apixaban may be used with caution, at a dose of 5 mg twice daily, reducible to 2.5 mg twice daily in certain cases 7

Transition Protocol

• When switching from dabigatran to apixaban, it is recommended to wait until the INR falls to approximately 2.0 before initiating the new anticoagulant, with a washout period of 24-48 hours depending on renal function 8, 9

Safety and Efficacy

• Apixaban has a lower risk of intracranial hemorrhage compared to warfarina and other direct oral anticoagulants, with a demonstrated safety and efficacy profile in the ARISTOTLE study, even in patients with moderate renal impairment 7, 8

Apixaban Use in Renal Failure

Introduction to Apixaban in Renal Impairment

• The American College of Cardiology recommends apixaban 5 mg twice daily for stable hemodialysis patients, with dose reduction to 2.5 mg twice daily if age ≥80 years or weight ≤60 kg 10

Pharmacokinetics and Dosing

• Apixaban has the lowest renal clearance (27%) compared to rivaroxaban (66%), edoxaban (50%), and dabigatran (80%) 10
• Pharmacokinetic data show that 2.5 mg twice daily in dialysis patients produces drug exposure comparable to 5 mg twice daily in patients with normal renal function 10

Comparison to Other Anticoagulants

• Switch from dabigatran to apixaban when CrCl falls below 50 mL/min, especially in the 30-50 mL/min range 10
• Edoxaban is absolutely contraindicated in ESRD or dialysis and should never be used 10

Clinical Considerations

• All anticoagulants carry increased bleeding risk in severe renal impairment 10
• Bleeding can occur at uncommon sites (pleura, pericardium, intracranial space) in severe kidney disease 10

Guideline Recommendations

• The European Heart Rhythm Association does not recommend routine NOAC use in CrCl <15 mL/min or dialysis due to limited hard endpoint data 10
• The evidence base in ESRD is primarily pharmacokinetic and observational, not from randomized trials 10

Apixaban Dosing and Renal Function

Standard Dosing Algorithm by Renal Function

• The European Society of Cardiology recommends a standard dose of 5 mg twice daily for patients with normal to moderate renal impairment (eGFR ≥30 mL/min), with a reduction to 2.5 mg twice daily only if the patient meets at least 2 of 3 criteria: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL 11, 12
• For patients with eGFR >50 mL/min, the standard dose is 5 mg twice daily, with no dose adjustment required based on renal function alone 11, 12
• The European Heart Journal guidelines suggest applying dose reduction criteria if ≥2 of the following are present: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL 11, 12

Renal Function Assessment

• The European Society of Cardiology recommends using the Cockcroft-Gault equation for dosing decisions, as this was used in pivotal trials, and reassessing renal function at least annually, or more frequently if clinical deterioration occurs 11, 12
• The European Heart Journal guidelines suggest monitoring renal function more frequently in patients with eGFR 30-50 mL/min or declining renal function 11, 12, 13

Comparison to Other DOACs by Renal Clearance

• Rivaroxaban requires a dose reduction to 15 mg daily if CrCl 30-49 mL/min, according to the European Heart Journal guidelines 11, 12
• Dabigatran is contraindicated if CrCl <30 mL/min in Europe, as stated in the European Heart Journal guidelines 11, 12

Evidence Quality Considerations

• Dosing recommendations for eGFR >30 mL/min are based on high-quality RCT data from the ARISTOTLE trial with 18,201 patients 11, 14
• The European Society of Cardiology notes that no RCTs exist for severe CKD (CrCl <25-30 mL/min) or dialysis patients 11, 12, 13

Apixaban Dosing in Chronic Kidney Disease

Dosing Recommendations

• The American Heart Association recommends starting with 5 mg twice daily as the standard dose for stable hemodialysis patients, and reducing to 2.5 mg twice daily if the patient meets at least one of these criteria: age ≥80 years OR body weight ≤60 kg 15
• Apixaban has the lowest renal clearance (27%) among all direct oral anticoagulants, making it the preferred DOAC in severe renal impairment, according to the American College of Chest Physicians 16

Renal Function Assessment

• The American Heart Association recommends calculating creatinine clearance using the Cockcroft-Gault method, as this was used in pivotal trials 15
• The American College of Chest Physicians suggests reassessing renal function every 1-3 months in patients pending dialysis, given the dynamic nature of declining kidney function 16

Drug Interactions and Bleeding Risk

• The American Heart Association advises avoiding concomitant use of dual P-glycoprotein and strong CYP3A4 inhibitors or inducers, particularly in CKD patients 15
• The American College of Chest Physicians recommends avoiding concomitant antiplatelet therapy, including low-dose aspirin, as this substantially elevates bleeding risk in CKD patients 16

Evidence Quality and Guideline Consensus

• The American Heart Association states there are no published studies supporting a dose for end-stage CKD not on dialysis (Level of Evidence: C) 15
• The American College of Chest Physicians recommends individualized decision-making for CrCl <15 mL/min not on dialysis (Ungraded consensus-based statement) 16

Baclofen and Apixaban Interaction: Evidence‑Based Pharmacokinetic Guidance

Pharmacokinetic Relationship

• No clinically significant drug‑drug interaction has been documented between baclofen and apixaban; baclofen does not inhibit or induce P‑glycoprotein nor CYP3A4, and therefore does not alter apixaban’s bioavailability or clearance. This conclusion is based on mechanistic studies published in the Journal of Thrombosis and Haemostasis (2013)【17】【18】.

Metabolic Pathways of Apixaban

• Apixaban is primarily metabolized by the cytochrome P450 3A4 enzyme and is a substrate of the P‑glycoprotein (P‑gp) efflux transporter. These pharmacokinetic characteristics were described in the same 2013 Journal of Thrombosis and Haemostasis articles【17】【18】.

Clinical Dosing Recommendations

• Apixaban dose should not be reduced solely because a patient is receiving baclofen, as there is no pharmacokinetic interaction that warrants dose adjustment. This practical recommendation follows the evidence presented in the 2013 Journal of Thrombosis and Haemostasis publications【17】【18】.